Slide 1: Q2 2021 Financial Results
We engineer enzymes to improve health… of people and the planet Q2 2021 Financial Results August 5, 2021
Slide 2: Forward Looking Statements
Forward Looking Statements • These slides and any accompanying oral presentation contain forward-looking statements that involve risks and uncertainties, including Codexis’ guidance on 2021 total revenues, product revenues and product gross margin. These statements relate to future events or our fut
Slide 3: Growth Drivers Continue to Accelerate
Growth Drivers Continue to Accelerate Strong Q2’21 Results Executing on Growth Opportunities Total revenue growth of 70% YOY Sustainable Manufacturing - Pharma: Breakthrough new application becomes largest annual product sale in Company history Quarterly Product Revenue More Than Sustainable Manufac
Slide 4: Codexis Pipeline Snapshot – June 30th 2021
Codexis Pipeline Snapshot – June 30th 2021 Commercial Pre-Commercial Pipeline vs. prior Sustaining pipeline Pipeline Project or Product Category Programs Total Revenues GUIDE TO THE PIPELINE SNAPSHOT Codexis Customer Product Sales 06/30/2021 6/30/2020 Row Headers Self-funded Partnered and/or Licensi
Slide 5: Strong and Growing Pipeline Opportunities
Strong and Growing Pipeline Opportunities Total Pipeline Growth: 2017 - 2021 Pipeline Distribution and Growth by Segment: 2017 - 2021 Commercialized (Product Sales/Licensing) Pre-commercial: Customer-partnered Pre-commercial: Codexis-funded Jun '17 Jun '19 Jun '21 90 24 22 80 20 18 70 17 60 16 15 13
Slide 6: Sustainable Manufacturing: Solid, Growing Base with Expanding Margins
Sustainable Manufacturing: Solid, Growing Base with Expanding Margins % Total 2020 Performance Enzymes Revenue Largest Annual Product Sale in Company History • $13.9M enzyme order secured in June Sustainable Manufacturing - • Undisclosed pharmaceutical partner Food & Industrial • Customer’s API - fa
Slide 7: Life Science Tools: High Growth
Life Science Tools: High Growth TdT Polymerase for Enzymatic DNA Synthesis Strong Progress in Q2’21 • TdT catalyzes the addition of nucleotides to a given DNA strand without the need for a template • Progress in marketing Codex® HiCap RNA and • Codexis is engineering a TdT polymerase to outperform C
Slide 8: Biotherapeutics: Rapid Pipeline Expansion and Validation
Biotherapeutics: Rapid Pipeline Expansion and Validation Preclinical Clinical # of Program Discovery Research IND Enabling Phase I Multi-program Gene Therapy Collaboration • Fabry Disease – CDX-6311, preclinical PoC 2016 1 1 • Pompe Disease – Advancing lead candidates • Undisclosed blood clotting fa
Slide 9: Strong Q2 2021 Results
Strong Q2 2021 Results $25.5M $14.7M 71% Q2’21 Total Q2’21 Product Gross Product Margin Revenue +70% Revenue +227% vs. 62% in Q2’20 $129.5M Cash Available for $21.6M $3.9M Growth. No Debt Performance Novel Enzymes Biotherapeutics $12.8M $12.8M $(4.3)M R&D Expense SG&A Expense Net Loss 9
Slide 10: Raised 2021 Guidance
Raised 2021 Guidance $98-103M $59-63M 65-68% Total Revenue Product Revenue Product Gross Margin
Slide 11: Executing 2021 Corporate Goals and Catalysts
Executing 2021 Corporate Goals and Catalysts ❑ Enzymes for Phase 2 / 3 pharma processes commercialize into new recurring product revenues Sustainable ❑ Continue widening pharma adoption and advancing clients to new CodeEvolver® platform deals Manufacturing ❑ $M+ food enzymes revenues from Tate & Lyl
Slide 12: We engineer enzymes to improve health of people and the planet
We engineer enzymes to improve health… of people and the planet Nasdaq: CDXS www.codexis.com